Abstract
Regeneron Pharmaceuticals has licensed technology from AstraZeneca’s MedImmune arm for making antibody-drug conjugates (ADCs) as cancer treatments. In exchange for a fee and milestone payments, Regeneron gets rights to use MedImmune’s method for linking a pyrrolobenzodiazepine-based cytotoxic drug to an antibody. Similarly, Oxford BioTherapeutics has licensed Nerviano Medical Sciences’ drug-linker technology. Nerviano will make and supply the cytotoxic-drug-and-linker combination, which is based on DNA-intercalating duocarmycin analogs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
